Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin versus tolvaptan in adults with autosomal dominant polycystic kidney disease
2018-000477-77Phase 3Active
- Sponsor
- Nephrology, Dialysis and Transplantation Unit, Policlinico di Bari
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Metformin with Tolvaptan (2 arms). Primary endpoint: Annualized slope of eGFR. Started Nov 2020; status: active.
02
Drugs
metformintolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2018-000477-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000477-77.